+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epstein Barr Virus (EBV) - Market Insight, Epidemiology and Market Forecast 2030

  • ID: 5292795
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 204 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AlloVir
  • Atara Biotherapeutics
  • Atara Biotherapeutics
  • Eutilex
  • Labolife
  • Merck
  • MORE
This ‘Epstein-Barr virus (EBV) - Market Insights, Epidemiology, and Market Forecast - 2030’ report deliver an in-depth understanding of the Epstein-Barr virus (EBV), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epstein-Barr virus (EBV) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted EBV symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Epstein-Barr virus (EBV) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:
2017-2030

Epstein-Barr virus (EBV) Disease Understanding and Treatment Algorithm

Epstein-Barr virus (EBV) Overview

Epstein-Barr virus (EBV) is a member of the Herpesviridae family and is a ubiquitous pathogen that is persistently harbored by people throughout the world. EBV is the major cause of infectious mononucleosis and is associated with several malignancies. EBV is an oncogenic virus and continued to attract considerable attention worldwide, primarily due to its oncogenic properties and its association with several human malignancies, including Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), post-transplant lymphoproliferative disease (PTLD) after organ or stem cell transplant, Hodgkin’s lymphoma (HL) and gastric carcinoma (GC). A detailed understanding of the risk factors or causes of cancer is of paramount importance for any future prevention strategies.

The sign and symptoms of IM comprise fatigue, fever, nausea, sore throat, cough, body aches, rash, photophobia, swollen lymph nodes in the neck and armpits, and rarely, splenomegaly (enlarged spleen) and hepatomegaly (enlarged liver). Primary EBV infection or reactivation in the immunocompromised host (particularly those post-hematopoietic stem cell transfer or solid organ transfer) may present as a life-threatening disease characterized by fever, lymphadenopathy, mononucleosis-like syndrome, central nervous system (CNS) disease/myelitis, pneumonia, sepsis-like syndrome, and PTLD. EBV can infect a wide range of cells and tissues including T and B lymphocytes, nasopharynx and oropharynx squamous epithelial cells, salivary and stomach glands, thyroid glandular epithelial cells, smooth muscle, and follicular dendritic cells. However, EBV primarily infects and replicates in the stratified squamous epithelium of the oropharynx, followed by a latent infection of B lymphocytes.

In the context of treatment, at present, there is no specific treatment for IM. Management focuses on symptomatic relief, and patients are therefore treated with simple anti-viral drugs, analgesics, antipyretics, hydration, and rest. Additionally, for the treatment of EBV-associated diseases investigational therapies and the treatment of PTLD, particularly in the setting of allogeneic hematopoietic stem cell transplant (HSCT) where adoptive immunotherapy (either donor lymphocyte infusion or infusion of EBV-specific lymphocytes) has demonstrated to be effective.

Epstein-Barr virus (EBV) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Epstein-Barr virus (EBV) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Epstein-Barr virus (EBV) market report gives a thorough understanding of EBV symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides EBV symptoms of treatment algorithms and treatment guidelines for EBV symptoms in the US, Europe, and Japan.

Epstein-Barr virus (EBV) Epidemiology

Epstein-Barr virus symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Epstein-Barr virus (EBV) epidemiology segmented as the Total Diagnosed cases of EBV Infectious Mononucleosis, Total Incident cases of EBV+ Cancers, Total Incident cases of EBV+ PTLD. The report includes the scenario of EBV symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Epstein-Barr virus (EBV) Epidemiology

The epidemiology segment also provides the Epstein-Barr virus (EBV) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

In 2020, the total diagnosed cases of EBV Infectious Mononucleosis in the US were found to be 162,800; whereas the EBV Lymphoma such as the Burkitt lymphoma (BL), Hodgkin lymphoma (HL) is in 1,555; 9,548 respectively. The EBV-cancer such as Gastric carcinoma (GC) cases were 27,619, and nasopharyngeal carcinoma (NPC) cases were 2,197 for the year 2020.

Epstein-Barr virus (EBV) Drug Chapters

The drug chapter segment of the Epstein-Barr virus (EBV) report encloses the detailed analysis of EBV marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Epstein-Barr virus (EBV) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Treatment is generally supportive of mononucleosis. Antipyretics and anti-inflammatory medications help treat fever, sore throat, and the general fatigue seen in this illness. Hydration, rest, and good nutritional intake should also be encouraged. Corticosteroids are not generally recommended in the routine treatment of mononucleosis because of concerns with immunosuppression; however, in cases of airway obstruction, corticosteroids are indicated along with appropriate airway management.

Epstein-Barr virus (EBV) Emerging Drugs

Viralym-M (AlloVir) is a multi-virus specific T cell therapy (VST) targeting five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr Virus (EBV), and Human Herpesvirus 6 (HHV-6), that has the potential to transform care for transplant recipients as well as individuals who are at high risk for opportunistic viral infections by reducing or preventing disease morbidity and dramatically improving patient outcomes. The drug has received Orphan Drug Designation, Priority Medicines (PRIME) designation in EU and Regenerative Medicine Advanced Therapy (RMAT) designation from the US for the treatment of serious infections with BK virus, cytomegalovirus, human herpes virus-6, Epstein-Barr virus, and/or adenovirus in allogeneic hematopoietic stem cell transplantation (HSCT) recipients.

Epstein-Barr virus (EBV) Market Outlook

The Epstein-Barr virus (EBV) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Epstein-Barr virus (EBV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Epstein-Barr virus (EBV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Epstein-Barr virus (EBV) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Epstein-Barr virus (EBV) market in 7MM. The market size of EBV in the seven major markets was found to be USD 1,673.44 million in 2020.

The United States Market Outlook

This section provides a total of Epstein-Barr virus (EBV) market size and market size by therapies in the United States.

The United States accounts for the highest market size of EBV in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Treatment options for EBV-PTLD include manipulating the balance between outgrowing EBV-infected B cells and the EBV CTL response and targeting the B cells with monoclonal antibodies or chemotherapy. In EBV-PTLD, select cases may benefit from the reduction of immunosuppression as the sole intervention or as part of the treatment plan. The current treatment market majorly includes the CD-20 Targeted Rituximab as monotherapy or Rituximab in combination with CHOP to control the cell proliferation in tumors and PTLD.

EU-5 Countries: Market Outlook

EBV-specific cytotoxic T-cell infusions have proven effective in EBV-PTLD and expanding such adoptive immunotherapies to other EBV-related malignancies is an area of active research. However, other EBV-related lymphomas typically have more restricted, less immunogenic arrays of viral antigens to target with adoptive immunotherapy compared to EBV-PTLD therapeutically. Furthermore, the malignant EBV-positive tumor cells of Hodgkin lymphoma are scattered amid a dense infiltrate of regulatory T-cells, macrophages, and other cells that may dampen the anti-tumor efficacy of adoptive immunotherapy. Strategies to overcome these obstacles are areas of ongoing pre-clinical and clinical investigations.

Although a wide number of studies are related to EBV detection, studies investigating the EBV viremia and genetic variability in healthy individuals are still limited, although this virus is transfusion transmissible and linked to PTLDs and a wide range of other malignancies. Estimates of EBV infection are important to give researchers and clinicians accurate data concerning the prevalence of the virus, and consequently, improving the safety of health practices to eliminate the EBV spread, especially in blood banks, and organ transplantation centers where EBV constitutes a life-threatening risk to recipients.

Japan Market Outlook

The total Epstein-Barr virus (EBV) market size and market size by therapies in Japan are also mentioned.

Epstein-Barr virus (EBV) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers the Epstein-Barr virus (EBV) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Epstein-Barr virus (EBV) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses the Epstein-Barr virus (EBV) key players involved in developing targeted therapeutics.

Major players include Brentuximab Vedotin (Seagen) is evaluated as the first line of therapy, whereas Tabelecleucel (Atara Biotherapeutics), Viralym-M (AlloVir), TT10 (Tessa Therapeutics), VRx-3996 + Valganciclovir (Viracta Therapeutics), FLX475 (RAPT Therapeutics)

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Epstein-Barr virus (EBV) emerging therapies.

Reimbursement Scenario in Epstein-Barr virus (EBV)

The cost-effectiveness model adapted from the Institute of Medicine (IOM) study of priorities for vaccine development proposed that the EBV vaccine was feasible and that licensure could occur within the time frame of its charge but was not imminent. The model estimated that it would take 15 years until licensure and that USD 390 million needed to be invested. Furthermore, it was estimated that this would be a relatively low-cost vaccine, costing USD 50 per dose. Vaccine administration would cost an additional USD 10. The committee accepted default assumptions for the vaccine that it would require a series of three doses and that effectiveness would be 75%.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Epstein-Barr virus (EBV) domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or the Epstein-Barr virus (EBV) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Epstein-Barr virus (EBV) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Epstein-Barr virus (EBV), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Epstein-Barr virus (EBV) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epstein-Barr virus (EBV) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Epstein-Barr virus (EBV) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epstein-Barr virus (EBV) market
Report Highlights
  • In the coming years, Epstein-Barr virus (EBV) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epstein-Barr virus (EBV) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for EBV. The launch of emerging therapies will significantly impact the Epstein-Barr virus (EBV) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for EBV.
  • the in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Epstein-Barr virus (EBV) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Epstein-Barr virus (EBV) Pipeline Analysis
  • Epstein-Barr virus (EBV) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Epstein-Barr virus (EBV) Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Epstein-Barr virus (EBV) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Epstein-Barr virus (EBV) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What were the Epstein-Barr virus (EBV) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Epstein-Barr virus (EBV) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Epstein-Barr virus (EBV) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Epstein-Barr virus (EBV) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Epstein-Barr virus (EBV) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Epstein-Barr virus (EBV) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden, and unmet needs of the Epstein-Barr virus (EBV)?
  • What is the historical Epstein-Barr virus (EBV) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Epstein-Barr virus (EBV) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Epstein-Barr virus (EBV)?
  • Out of all 7MM countries, which country would have the highest population of Epstein-Barr virus (EBV) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Epstein-Barr virus (EBV)?
  • What are the current treatment guidelines for the treatment of Epstein-Barr virus (EBV) in the USA, Europe, and Japan?
  • What are the Epstein-Barr virus (EBV) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Epstein-Barr virus (EBV)?
  • How many therapies are developed by each company for the treatment of Epstein-Barr virus (EBV)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Epstein-Barr virus (EBV)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epstein-Barr virus (EBV) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Epstein-Barr virus (EBV) and their status?
  • What are the key designations that have been granted for the emerging therapies for Epstein-Barr virus (EBV)?
  • What are the global historical and forecasted market of Epstein-Barr virus (EBV)?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Epstein-Barr virus (EBV) market
  • To understand the future market competition in the Epstein-Barr virus (EBV) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Epstein-Barr virus (EBV) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Epstein-Barr virus (EBV) market
  • To understand the future market competition in the Epstein-Barr virus (EBV) market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlloVir
  • Atara Biotherapeutics
  • Atara Biotherapeutics
  • Eutilex
  • Labolife
  • Merck
  • MORE
1. Key Insights

2. Epstein-Barr Virus: Market Overview at a Glance
2.1. Market Share (%) Distribution of EBV in 2017
2.2. Market Share (%) Distribution of EBV in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Epstein-Barr Virus (EBV)
5.1. Introduction
5.2. Classification
5.3. Signs and Symptoms
5.4. Etiology
5.5. Pathogenesis
5.6. EBV Associated Diseases
5.7. Diagnosis
5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM
6.3. Total Incident Population of EBV+ Cancers and PTLD in 7MM

7. 7MM Epidemiology of EBV
7.1. Assumptions and Rationale
7.2. The United States
7.2.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the US
7.2.2. Total Incident cases of EBV+ Cancers in the US
7.2.3. Total Incident cases of EBV+ PTLD in the US
7.3. Germany
7.3.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Germany
7.3.2. Total Incident cases of EBV+ Cancers in Germany
7.3.3. Total Incident cases of EBV+ PTLD in Germany
7.4. France
7.4.1. Total Diagnosed cases of EBV Infectious Mononucleosis in France
7.4.2. Total Incident cases of EBV+ Cancers in France
7.4.3. Total Incident cases of EBV+ PTLD in France
7.5. Italy
7.5.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Italy
7.5.2. Total Incident cases of EBV+ Cancers in Italy
7.5.3. Total Incident cases of EBV+ PTLD in Italy
7.6. Spain
7.6.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Spain
7.6.2. Total Incident cases of EBV+ Cancers in Spain
7.6.3. Total Incident cases of EBV+ PTLD in Spain
7.7. The United Kingdom
7.7.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the UK
7.7.2. Total Incident cases of EBV+ Cancers in the UK
7.7.3. Total Incident cases of EBV+ PTLD in the UK
7.8. Japan
7.8.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Japan
7.8.2. Total Incident cases of EBV+ Cancers in Japan
7.8.3. Total Incident cases of EBV+ PTLD in Japan

8. Treatment and Management

9. Unmet Needs

10. Emerging Therapies
10.1. Key Cross Competition
10.2. Tabelecleucel: Atara Biotherapeutics
10.2.1. Drug Description
10.2.2. Other development activities
10.2.3. Clinical development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Viralym-M: AlloVir
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. TT10: Tessa Therapeutics
10.4.1. Drug Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. Nanatinostat: Viracta Therapeutics
10.5.1. Drug Description
10.5.2. Other development activities
10.5.3. Clinical Development
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.6. Brentuximab Vedotin: Seagen
10.6.1. Drug Description
10.6.2. Other development activities
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. FLX475: RAPT Therapeutics
10.7.1. Drug Description
10.7.2. Other development Activities
10.7.3. Clinical development
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Other Potential Therapies
10.9. Pembrolizumab: Merck
10.9.1. Drug Description
10.9.2. Clinical Development
10.9.3. Product Profile
10.10. EBViNT: Eutilex
10.10.1. Drug description
10.10.2. Other Development Activities
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile
10.11. ATA188: Atara Biotherapeutics
10.11.1. Drug Description
10.11.2. Clinical Development
10.11.3. Safety and Efficacy
10.11.4. Product Profile
10.12. 2LEBV and 2LXFS: Labolife
10.12.1. Drug Description
10.12.2. Clinical development
10.12.3. Product Profile

11. Epstein-Barr Virus: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of EBV in 7MM

12. Market Outlook: 7MM
12.1. EBV-Vaccine
12.2. EBV+ Cancers/PTLD
12.3. The United States Market Size
12.3.1. The Total Market Size of EBV in the United States
12.3.2. The Market Size of EBV Infectious Mononucleosis in the United States
12.3.3. The Market Size of EBV+ Cancers and PTLD in the United States (1L)
12.3.4. The Market Size of EBV+ Cancers and PTLD in the United States (R/R)
12.4. Germany Market Size
12.4.1. The Total Market Size of EBV in Germany
12.4.2. The Market Size of EBV Infectious Mononucleosis in Germany
12.4.3. The Market Size of EBV+ Cancers and PTLD in Germany (1L)
12.4.4. The Market Size of EBV+ Cancers and PTLD in Germany (R/R)
12.5. France Market Size
12.5.1. The Total Market Size of EBV in France
12.5.2. The Market Size of EBV Infectious Mononucleosis in France
12.5.3. The Market Size of EBV+ Cancers and PTLD in France (1L)
12.5.4. The Market Size of EBV+ Cancers and PTLD in France (R/R)
12.6. Italy Market Size
12.6.1. The Total Market Size of EBV in Italy
12.6.2. The Market Size of EBV Infectious Mononucleosis in Italy
12.6.3. The Market Size of EBV+ Cancers and PTLD in Italy (1L)
12.6.4. The Market Size of EBV+ Cancers and PTLD in Italy (R/R)
12.7. Spain Market Size
12.7.1. The Total Market Size of EBV in Spain
12.7.2. The Market Size of EBV Infectious Mononucleosis in Spain
12.7.3. The Market Size of EBV+ Cancers and PTLD in Spain (1L)
12.7.4. The Market Size of EBV+ Cancers and PTLD in Spain (R/R)
12.8. The UK Market Size
12.8.1. The Total Market Size of EBV in the UK
12.8.2. The Market Size of EBV Infectious Mononucleosis in the UK
12.8.3. The Market Size of EBV+ Cancers and PTLD in the UK (1L)
12.8.4. The Market Size of EBV+ Cancers and PTLD in the UK (R/R)
12.9. Japan Market Size
12.9.1. The Total Market Size of EBV in Japan
12.9.2. The Market Size of EBV Infectious Mononucleosis in Japan
12.9.3. The Market Size of EBV+ Cancers and PTLD in Japan (1L)
12.9.4. The Market Size of EBV+ Cancers and PTLD in Japan (R/R)

13. Market Drivers

14. Market Barriers

15. Market Access

16. SWOT Analysis

17. Case Studies
17.1. How I treat T-cell chronic active Epstein-Barr virus disease
17.2. Chronic Active Epstein-Barr virus Infection Mimicking Diabetic Ketoacidosis
17.3. Epstein-Barr virus Infection in an Elderly Non-immunocompromised Adult Successfully Treated with Rituximab

18. KOL Views

19. Bibliography

20. Appendix
20.1. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

List of Tables
Table 1: Prevalence of signs, symptoms, and laboratory abnormalities in infectious mononucleosis
Table 2: Complications reported in ≥1% of cases of infectious mononucleosis
Table 3: Biological activities of Epstein Barr virus latency stage gene products
Table 4:Expression of EBV latent genes associated with latency programs
Table 5: EBV associated diseases
Table6: Epstein-Barr virus-positive versus Epstein-Barr virus-negative PTLD
Table 7: Early versus late-onset PTLD in adults
Table 8: Serological profiles in EBV reactivation and EBV-associated diseases
Table 9: Interpretation of Epstein-Barr virus serological profiles in immunocompetent patients
Table 10: Interpretation of IgG avidity test with immunoblotting
Table 11: Advantages and Disadvantages of various EBV diagnostic methods
Table 12: Differential Diagnosis
Table 13: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017-2030)
Table 14: Total Incident Population of EBV+ Cancers and PTLD in 7MM
Table 15: Major Sources used to derive cancer and transplantation cases
Table 16: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)
Table 17: Total Incident Cases of EBV+ Cancers in the US (2017-2030)
Table 18: Total Incident Cases of EBV+ PTLD in the US (2017-2030)
Table 19: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)
Table 20: Total Incident Cases of EBV+ Cancers in Germany (2017-2030)
Table 21: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)
Table 22: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)
Table 23: Total Incident Cases of EBV+ Cancers in France (2017-2030)
Table 24: Total Incident Cases of EBV+ PTLD in France (2017-2030)
Table 25: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)
Table 26: Total Incident Cases of EBV+ Cancers in Italy (2017-2030)
Table 27: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)
Table 28: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)
Table 29: Total Incident Cases of EBV+ Cancers in Spain (2017-2030)
Table 30: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)
Table 31: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)
Table 32: Total Incident Cases of EBV+ Cancers in the UK (2017-2030)
Table 33: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)
Table 34: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)
Table 35: Total Incident Cases of EBV+ Cancers in Japan (2017-2030)
Table 36: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)
Table 37: Available therapies for EBV diseases
Table 38:Treatment Recommendation for PTLD
Table 39: Tabelecleucel, Clinical Trial Description, 2020
Table 40: Viralym-M, Clinical Trial Description, 2020
Table 41: TT10, Clinical Trial Description, 2020
Table 42: VRx-3996, Clinical Trial Description, 2020
Table 43: Brentuximab Vedotin, Clinical Trial Description, 2020
Table 44: FLX475, Clinical Trial Description, 2020
Table 45: Bevacizumab and Pembrolizumab, Clinical Trial Description, 2020
Table 46: EBViNT, Clinical Trial Description, 2020
Table 47: ATA188, Clinical Trial Description, 2020
Table 48: 2LEBV and 2LXFS, Clinical Trial Description, 2020
Table 49: Market Size of EBV in 7MM in USD Million (2017-2030)
Table 50: Market Size of EBV in the US in USD Million (2017-2030)
Table 51: Market Size of EBV Infectious Mononucleosis in the US in USD Million (2017-2030)
Table 52: The US Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 53: The US Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 54: Market Size of EBV in Germany in USD Million (2017-2030)
Table 55: Market Size of EBV Infectious Mononucleosis in Germany in USD Million (2017-2030)
Table 56: Germany Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 57: Germany Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 58: Market Size of EBV in France in USD Million (2017-2030)
Table 59: Market Size of EBV Infectious Mononucleosis in France in USD Million (2017-2030)
Table 60: France Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 61: France Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 62: Market Size of EBV in Italy in USD Million (2017-2030)
Table 63: Market Size of EBV Infectious Mononucleosis in Italy in USD Million (2017-2030)
Table 64: Italy Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 65: Italy Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 66: Market Size of EBV in Spain in USD Million (2017-2030)
Table 67: Market Size of EBV Infectious Mononucleosis in Spain in USD Million (2017-2030)
Table 68: Spain Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 69: Spain Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 70: Market Size of EBV in the UK in USD Million (2017-2030)
Table 71: Market Size of EBV Infectious Mononucleosis in the UK in USD Million (2017-2030)
Table 72: The UK Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 73: The UK Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)
Table 74: Market Size of EBV in Japan in USD Million (2017-2030)
Table 75: Market Size of EBV Infectious Mononucleosis in Japan in USD Million (2017-2030)
Table 76: Japan Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017-2030)
Table 77:Japan Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017-2030)

List of Figures
Figure 1: Classification of the EBV virus
Figure 2: Symptoms of Infectious Mononucleosis
Figure 3: Risk factors associated with EBV infection
Figure 4: Cell transformation and cell proliferation of tumor cell lines in EBV-cancers
Figure 5: The Epstein-Barr virus genome
Figure 6: Putative in vivo interactions between Epstein-Barr virus and host cells
Figure 7: Activities of Selected EBV Proteins
Figure 8: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017-2030)
Figure 9: Total Incident Population of EBV+ Cancers and PTLD in 7MM (2017-2030)
Figure 10: Global burden of EBV-attributable malignancies- 2017
Figure 11: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)
Figure 12: Total Incident Cases of EBV+ Cancer in the US (2017-2030)
Figure 13: Total Incident Cases of EBV+ PTLD in the US (2017-2030)
Figure 14: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)
Figure 15: Total Incident Cases of EBV+ Cancer in Germany (2017-2030)
Figure 16: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)
Figure 17: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)
Figure 18: Total Incident Cases of EBV+ Cancer in France (2017-2030)
Figure 19: Total Incident Cases of EBV+ PTLD in France (2017-2030)
Figure 20: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)
Figure 21: Total Incident Cases of EBV+ Cancer in Italy (2017-2030)
Figure 22: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)
Figure 23: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)
Figure 24: Total Incident Cases of EBV+ Cancer in Spain (2017-2030)
Figure 25: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)
Figure 26: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)
Figure 27: Total Incident Cases of EBV+ cancer in the UK (2017-2030)
Figure 28: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)
Figure 29: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)
Figure 30: Total Incident Cases of EBV+ Cancer in Japan (2017-2030)
Figure 31: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)
Figure 32: Treatment of IM
Figure 33: Algorithm for management and treatment of PTLD
Figure 34: Treatment algorithm of PTLD
Figure 35: Prevention of EBV infection
Figure 36: Unmet Needs
Figure 37: Market Size of EBV in USD Million (2017-2030)
Figure 38: Market Size of EBV in the US, USD Millions (2017-2030)
Figure 39: Market Size of EBV Infectious Mononucleosis in the US, USD Millions (2017-2030)
Figure 40: Market Size of EBV+ Cancers and PTLD in the US (1L), USD Millions (2017-2030)
Figure 41: Market Size of EBV+ Cancers and PTLD R/R in the US, USD Millions (2017-2030)
Figure 42: Market Size of EBV in Germany, USD Millions (2017-2030)
Figure 43: Market Size of EBV Infectious Mononucleosis in Germany, USD Millions (2017-2030)
Figure 44: Market Size of EBV+ Cancers and PTLD in Germany (1L), USD Millions (2017-2030)
Figure 45: Market Size of EBV+ Cancers and PTLD R/R in Germany, USD Millions (2017-2030)
Figure 46: Market Size of EBV in France, USD Millions (2017-2030)
Figure 47: Market Size of EBV Infectious Mononucleosis in France, USD Millions (2017-2030)
Figure 48: Market Size of EBV+ Cancers and PTLD in France (1L), USD Millions (2017-2030)
Figure 49: Market Size of EBV+ Cancers and PTLD R/R in France, USD Millions (2017-2030)
Figure 50: Market Size of EBV in Italy, USD Millions (2017-2030)
Figure 51: Market Size of EBV Infectious Mononucleosis in Italy, USD Millions (2017-2030)
Figure 52: Market Size of EBV+ Cancers and PTLD in Italy (1L), USD Millions (2017-2030)
Figure 53: Market Size of EBV+ Cancers and PTLD R/R in Italy, USD Millions (2017-2030)
Figure 54: Market Size of EBV in Spain, USD Millions (2017-2030)
Figure 55: Market Size of EBV Infectious Mononucleosis in Spain, USD Millions (2017-2030)
Figure 56: Market Size of EBV+ Cancers and PTLD in Spain (1L), USD Millions (2017-2030)
Figure 57: Market Size of EBV+ Cancers and PTLD R/R in Spain, USD Millions (2017-2030)
Figure 58: Market Size of EBV in the UK, USD Millions (2017-2030)
Figure 59: Market Size of EBV Infectious Mononucleosis in the UK, USD Millions (2017-2030)
Figure 60: Market Size of EBV+ Cancers and PTLD in the UK (1L), USD Millions (2017-2030)
Figure 61: Market Size of EBV+ Cancers and PTLD R/R in the UK, USD Millions (2017-2030)
Figure 62: Market Size of EBV in Japan, USD Millions (2017-2030)
Figure 63: Market Size of EBV Infectious Mononucleosis in Japan, USD Millions (2017-2030)
Figure 64: Market Size of EBV+ Cancers and PTLD in Japan (1L), USD Millions (2017-2030)
Figure 65: Market Size of EBV+ Cancers and PTLD R/R in Japan, USD Millions (2017-2030)
Figure 66: Market Barriers
Figure 67: Market Barriers
Note: Product cover images may vary from those shown
3 of 3
  • Atara Biotherapeutics
  • AlloVir
  • Tessa Therapeutics
  • Viracta Therapeutics
  • Seagen
  • RAPT Therapeutics
  • Merck
  • Eutilex
  • Atara Biotherapeutics
  • Labolife
Note: Product cover images may vary from those shown
Adroll
adroll